Associations between the CYBA 242C/T and the MPO -463G/A polymorphisms, oxidative stress and cardiovascular disease in chronic kidney disease patients

Blood Purification

Volumn 25, Issue 2, 2007, Pages 210-218

  Grahl, Debora A ^a,b   Axelsson, Jonas ^a   Nordfors, Louise ^a   Heimbürger, Olof ^a   Bárány, Peter ^a   Qureshi, Abdul Rashid ^a   Kato, Sawako ^a   Watanabe, Makoto ^a   Suliman, Mohamed ^a   Riella, Miguel C ^b   Lindholm, Bengt ^a,c   Stenvinkel, Peter ^a   Pecoits Filho, Roberto ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular disease; Chronic kidney disease; Mortality; Myeloperoxidase; NADPH oxidase; Oxidative stress

Indexed keywords

MYELOPEROXIDASE; PLASMALOGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; CYBA PROTEIN, HUMAN; PEROXIDASE;

ADULT; AGED; ANAMNESIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DIALYSIS; DISEASE SEVERITY; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED;

ADULT; AGED; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; NADPH OXIDASE; OXIDATIVE STRESS; PEROXIDASE; POLYMORPHISM, GENETIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 33947418882     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100419     Document Type: Article

References (54)

1. Foley RN, Parfrey PS: Cardiovascular disease and mortality in ESRD. J Nephrol 1998;11:239-245.
2. Go AS, Chertow GM, Fan D, et al: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
3. Madamanchi NR, Vendrov A, Runge MS: Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005;25:29-38.
4. Stenvinkel P, Pecoits-Filho R, Lindholm B: Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 2003;14:1927-1939.
5. Himmelfarb J, Stenvinkel P, Ikizler TA, et al: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-1538.
6. Mosyagin I, Dettling M, Roots I, et al: Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol 2004;24:613-617.
7. Hoy A, Leininger-Muller B, Kutter D, et al: Growing significance of myeloperoxidase in non-infectious diseases. Clin Chem Lab Med 2002;40:2-8.
8. Piedrafita FJ, Molander RB, Vansant G, et al: An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996;271:14412-14420.
9. Pecoits-Filho R, Stenvinkel P, Marchlewska A, et al: A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl 2003:S172-S176.
10. Pagano PJ, Clark JK, Cifuentes-Pagano ME, et al: Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci USA 1997;94:14483-14488.
11. Guzik TJ, West NE, Black E, et al: Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000;102:1744-1747.
12. Stenvinkel P, Heimburger O, Paultre F, et al: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-1911.
13. Stenvinkel P, Heimburger O, Lindholm B, et al: Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000;15:953-960.
14. Stenvinkel P, Holmberg I, Heimburger O, et al: A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients. Nephrol Dial Transplant 1998;13:2594-2600.
15. Bjorkhem I, Sisfontes L, Bostrom B, et al: Simple diagnosis of the Zellweger syndrome by gas-liquid chromatography of dimethylacetals. J Lipid Res 1986;27:786-791.
16. TM and validation against the 5′nuclease (Taqman®) assay. Hum Mutat 2002;19:395-401.
17. Vaziri ND, Oveisi F, Ding Y: Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int 1998;53:1748-1754.
18. Hasdan G, Benchetrit S, Rashid G, et al: Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide. Kidney Int 2002;61:586-590.
19. Deng G, Vaziri ND, Jabbari B, et al: Increased tyrosine nitration of the brain in chronic renal insufficiency: reversal by antioxidant therapy and angiotensin-converting enzyme inhibition. J Am Soc Nephrol 2001;12:1892-1899.
20. Shainkin-Kestenbaum R, Caruso C, Berlyne GM: Reduced superoxide dismutase activity in erythrocytes of dialysis patients: a possible factor in the etiology of uremic anemia. Nephron 1990;55:251-253.
21. Durak I, Akyol O, Basesme E, et al: Reduced erythrocyte defense mechanisms against free radical toxicity in patients with chronic renal failure. Nephron 1994;66:76-80.
22. Eschbach JW, Adamson JW: Anemia of endstage renal disease (ESRD). Kidney Int 1985;28:1-5.
23. Turi S, Nemeth I, Vargha I, et al: Erythrocyte defense mechanisms against free oxygen radicals in haemodialysed uraemic children. Pediatr Nephrol 1991;5:179-183.
24. Daugherty A, Dunn JL, Rateri DL, et al: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994;94:437-444.
25. Hazen SL, Heinecke JW: 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997;99:2075-2081.
26. Eiserich JP, Baldus S, Brennan ML, et al: Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002;296:2391-2394.
27. Nikpoor B, Turecki G, Fournier C, et al: A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 2001;142:336-339.
28. Kutter D, Devaquet P, Vanderstocken G, et al: Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol 2000;104:10-15.
29. Azumi H, Inoue N, Takeshita S, et al: Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation 1999;100:1494-1498.
30. Warnholtz A, Nickenig G, Schulz E, et al: Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999;99:2027-2033.
31. Guzik TJ, West NE, Black E, et al: Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 2000;86:E85-E90.
32. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000;86:494-501.
33. Rubbo H, Tarpey M, Freeman BA: Nitric oxide and reactive oxygen species in vascular injury. Biochem Soc Symp 1995;61:33-45.
34. Mugge A, Elwell JH, Peterson TE, et al: Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ Res 1991;69:1293-1300.
35. Aviram M, Rosenblat M, Etzioni A, et al: Activation of NADPH oxidase required for macrophage-mediated oxidation of low-density lipoprotein. Metabolism 1996;45:1069-1079.
36. Marui N, Offermann MK, Swerlick R, et al: Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993;92:1866-1874.
37. Rajagopalan S, Meng XP, Ramasamy S, et al: Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996;98:2572-2579.
38. Griendling KK, Minieri CA, Ollerenshaw JD, et al: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-1148.
39. 2 in angiotensin II-induced vascular hypertrophy. Hypertension 1998;32:488-495.
40. Ushio-Fukai M, Zafari AM, Fukui T, et al: p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996;271:23317-23321.
41. Irani K, Xia Y, Zweier JL, et al: Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 1997;275:1649-1652.
42. 2 for platelet-derived growth factor signal transduction. Science 1995;270:296-299.
43. Hiraoka W, Vazquez N, Nieves-Neira W, et al: Role of oxygen radicals generated by NADPH oxidase in apoptosis induced in human leukemia cells. J Clin Invest 1998;102:1961-1968.
44. Cahilly C, Ballantyne CM, Lim DS, et al: A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ Res 2000;86:391-395.
45. Gardemann A, Mages P, Katz N, et al: The p22 phox A640G gene polymorphism but not the C242T gene variation is associated with coronary heart disease in younger individuals. Atherosclerosis 1999;145:315-323.
46. Li A, Prasad A, Mincemoyer R, et al: Relationship of the C242T p22phox gene polymorphism to angiographic coronary artery disease and endothelial function. Am J Med Genet 1999;86:57-61.
47. Saha N, Sanghera DK, Kamboh MI: The p22 phox polymorphism C242T is not associated with CHD risk in Asian Indians and Chinese. Eur J Clin Invest 1999;29:999-1002.
48. Renner W, Schallmoser K, Gallippi P, et al: C242T polymorphism of the p22 phox gene is not associated with peripheral arterial occlusive disease. Atherosclerosis 2000;152:175-179.
49. Mata-Balaguer T, de la Herran R, Ruiz-Rejon C, et al: Angiotensin-converting enzyme and p22(phox) polymorphisms and the risk of coronary heart disease in a low-risk Spanish population. Int J Cardiol 2004;95:145-151.
50. Kirk EA, Dinauer MC, Rosen H, et al: Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2000;20:1529-1535.
51. Kunsch C, Medford RM: Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999;85:753-766.
52. Zhang C, Yang J, Jacobs JD, et al: Interaction of myeloperoxidase with vascular NAD(P)H oxidase-derived reactive oxygen species in vasculature: implications for vascular diseases. Am J Physiol Heart Circ Physiol 2003;285:H2563-H2572.
53. Ito D, Murata M, Watanabe K, et al: C242T polymorphism of NADPH oxidase p22 PHOX gene and ischemic cerebrovascular disease in the Japanese population. Stroke 2000;31:936-939.
54. Cai H, Duarte N, Wilcken DE, et al: NADH/NADPH oxidase p22 phox C242T polymorphism and coronary artery disease in the Australian population. Eur J Clin Invest 1999;29:744-748.